Clinical Trial Update: Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating abciximab (ReoPro) for vaso-occlusive crises in sickle cell disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ReoPro (abciximab)

Snippet

Sponsor: St. Louis University | Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain | Phase 2 | Status: WITHDRAWN